Subscribe to our Newsletters !!

Aurobindo pharma

Aurobindo Pharma gets VAI arrangement from US controller for Hyderabad unit

Aurobindo Pharma on Tuesday said the US health controller has concluded that the examination arrangement of organization’s injectable detailing fabricating office at Hyderabad is voluntary action indicated (VAI). According to the USFDA, a VAI assessment grouping demonstrates that despite the fact that specialists found and recorded offensive conditions during the examination, FDA won’t make or

Aurobindo Pharma gets USFDA gesture for Flucytosine Capsules

Aurobindo Pharma Limited has gotten last endorsement from the US Food and Drug Administration (USFDA) to make and market Flucytosine Capsules, 250 mg and 500 mg. Flucytosine Capsules are conventional adaptation of Bausch Health’s Ancobon® Capsules. The item will be propelled in June 2020. The endorsed item has an expected market size of US$ 43

Aurobindo Pharma ties up with BIRAC to create COVID-19 immunization

Aurobindo Pharma on Tuesday announced collaboration with the Biotechnology Industry Research Assistance Council (BIRAC), set up by the Department of Biotechnology for the development of COVID-19 vaccine. Aurobindo Pharma said it is developing a vaccine for COVID-19 through its wholly-owned US subsidiary, Auro Vaccines. “Aurobindo is in the process of preparing a state-of-art manufacturing facility